Abstract:Interleukin (IL)-6 is a pleiotropic cytokine that not only affects the immune system, but also acts in other biological systems and many physiological events in various organs. In a target cell, IL-6 can simultaneously generate functionally distinct or sometimes contradictory signals through its receptor complex, IL-6Rα and gp130. One good illustration is derived from the in vitro observations that IL-6 promotes the growth arrest and differentiation of M1 cells through gp130-mediated STAT3 activation, whereas the Y759/SHP-2-mediated cascade by gp130 stimulation has growth-enhancing effects. The final physiological output can be thought of as a consequence of the orchestration of the diverse signaling pathways generated by a given ligand. This concept, the signal orchestration model, may explain how IL-6 can elicit proinflammatory or anti-inflammatory effects, depending on the in vivo environmental circumstances. Elucidation of the molecular mechanisms underlying this issue is a challenging subject for future research. Intriguingly, recent in vivo studies indicated that the SHP-2-binding site- and YXXQ-mediated pathways through gp130 are not mutually exclusive but affect each other: a mutation at the SHP-2-binding site prolongs STAT3 activation, and a loss of STAT activation by gp130 truncation leads to sustained SHP-2/ERK MAPK phosphorylation. Although IL-6/gp130 signaling is a promising target for drug discovery for many human diseases, the interdependence of each signaling pathway may be an obstacle to the development of a nonpeptide orally active small molecule to inhibit one of these IL-6 signaling cascades, because it would disturb the signal orchestration. In mice, a consequence of the imbalanced signals causes unexpected results such as gastrointestinal disorders, autoimmune diseases, and/or chronic inflammatory proliferative diseases. However, lessons learned from IL-6 KO mice indicate that IL-6 is not essential for vital biological processes, but a significant impact on disease progression in many experimental models for human disorders. Thus, IL-6/gp130 signaling will become a more attractive therapeutic target for human inflammatory diseases when a better understanding of IL-6 signaling, including the identification of the conductor for gp130 signal transduction, is achieved.

Biological and clinical aspects of interleukin 6

IL-6 in inflammation, immunity, and disease.

IL-6: from its discovery to clinical applications

Interleukin-6 as a Multifunctional Regulator: Inflammation, Immune Response, and Fibrosis

The Two-Faced Cytokine IL-6 in Host Defense and Diseases

Biology of Interleukin-17 and Its Pathophysiological Significance in Sepsis

IL-6 in inflammation, autoimmunity and cancer

Physiological and pathological roles of interleukin-6 in the central nervous system

IL-6 as a keystone cytokine in health and disease

IL-6 signal transduction and its physiological roles: the signal orchestration model

Interleukin-6 serves as a critical factor in various cancer progression and therapy

Progress in the Research of Structure and Function of Interleukin-6 Receptor

Interplay between interleukin-6 signaling and the vascular endothelium in cytokine storms

Translating IL-6 biology into effective treatments

The role of interleukin‐36 in health and disease states

Local and systemic effects of interleukin‐6 (IL‐6) in inflammation and cancer

Involvement of Interleukin 6 in Hepatitis B Viral Infection

Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway

Interleukin-6 as a Potential Therapeutic Target for Pulmonary Arterial Hypertension

Targeting IL-6 trans-signalling: past, present and future prospects

Endogenous Interleukin-6 Plays A Crucial Protective Role In Streptococcal Toxic Shock Syndrome Via Suppression Of Tumor Necrosis Factor Alpha Production